181 related articles for article (PubMed ID: 23033260)
1. Effectiveness of eplerenone or spironolactone treatment in preserving renal function in primary aldosteronism.
Fourkiotis V; Vonend O; Diederich S; Fischer E; Lang K; Endres S; Beuschlein F; Willenberg HS; Rump LC; Allolio B; Reincke M; Quinkler M;
Eur J Endocrinol; 2013 Jan; 168(1):75-81. PubMed ID: 23033260
[TBL] [Abstract][Full Text] [Related]
2. Effect of Eplerenone on the Glomerular Filtration Rate (GFR) in Primary Aldosteronism: Sequential Changes in the GFR During Preoperative Eplerenone Treatment to Subsequent Adrenalectomy.
Nakano Y; Yoshimoto T; Fukuda T; Murakami M; Bouchi R; Minami I; Hashimoto K; Fujii Y; Kihara K; Ogawa Y
Intern Med; 2018 Sep; 57(17):2459-2466. PubMed ID: 29709927
[TBL] [Abstract][Full Text] [Related]
3. Predictors of decreasing glomerular filtration rate and prevalence of chronic kidney disease after treatment of primary aldosteronism: renal outcome of 213 cases.
Iwakura Y; Morimoto R; Kudo M; Ono Y; Takase K; Seiji K; Arai Y; Nakamura Y; Sasano H; Ito S; Satoh F
J Clin Endocrinol Metab; 2014 May; 99(5):1593-8. PubMed ID: 24285678
[TBL] [Abstract][Full Text] [Related]
4. Comparison of eplerenone and spironolactone for the treatment of primary aldosteronism.
Karashima S; Yoneda T; Kometani M; Ohe M; Mori S; Sawamura T; Furukawa K; Seta T; Yamagishi M; Takeda Y
Hypertens Res; 2016 Mar; 39(3):133-7. PubMed ID: 26606875
[TBL] [Abstract][Full Text] [Related]
5. Long-term renal outcomes in patients with primary aldosteronism.
Sechi LA; Novello M; Lapenna R; Baroselli S; Nadalini E; Colussi GL; Catena C
JAMA; 2006 Jun; 295(22):2638-45. PubMed ID: 16772627
[TBL] [Abstract][Full Text] [Related]
6. Intrarenal hemodynamics in primary aldosteronism before and after treatment.
Sechi LA; Di Fabio A; Bazzocchi M; Uzzau A; Catena C
J Clin Endocrinol Metab; 2009 Apr; 94(4):1191-7. PubMed ID: 19141581
[TBL] [Abstract][Full Text] [Related]
7. Renal damage in primary aldosteronism: results of the PAPY Study.
Rossi GP; Bernini G; Desideri G; Fabris B; Ferri C; Giacchetti G; Letizia C; Maccario M; Mannelli M; Matterello MJ; Montemurro D; Palumbo G; Rizzoni D; Rossi E; Pessina AC; Mantero F;
Hypertension; 2006 Aug; 48(2):232-8. PubMed ID: 16801482
[TBL] [Abstract][Full Text] [Related]
8. Relative glomerular hyperfiltration in primary aldosteronism.
Ribstein J; Du Cailar G; Fesler P; Mimran A
J Am Soc Nephrol; 2005 May; 16(5):1320-5. PubMed ID: 15800124
[TBL] [Abstract][Full Text] [Related]
9. Sex Differences in Renal Outcomes After Medical Treatment for Bilateral Primary Aldosteronism.
Nakamaru R; Yamamoto K; Akasaka H; Rakugi H; Kurihara I; Yoneda T; Ichijo T; Katabami T; Tsuiki M; Wada N; Yamada T; Kobayashi H; Tamura K; Ogawa Y; Kawashima J; Inagaki N; Fujita M; Oki K; Kamemura K; Tanabe A; Naruse M;
Hypertension; 2021 Feb; 77(2):537-545. PubMed ID: 33356395
[TBL] [Abstract][Full Text] [Related]
10. Eplerenone improves carotid intima-media thickness (IMT) in patients with primary aldosteronism.
Matsuda Y; Kawate H; Matsuzaki C; Sakamoto R; Shibue K; Ohnaka K; Anzai K; Nomura M; Takayanagi R
Endocr J; 2016; 63(3):249-55. PubMed ID: 26727302
[TBL] [Abstract][Full Text] [Related]
11. Good blood pressure control on antihypertensives, not only response to spironolactone, predicts improved outcome after adrenalectomy for aldosteronoma.
Zarnegar R; Lee J; Brunaud L; Lindsay S; Kebebew E; Clark OH; Duh QY
Surgery; 2007 Dec; 142(6):921-9; discussion 921-9. PubMed ID: 18063077
[TBL] [Abstract][Full Text] [Related]
12. Primary aldosteronism: changes in cystatin C-based kidney filtration, proteinuria, and renal duplex indices with treatment.
Wu VC; Kuo CC; Wang SM; Liu KL; Huang KH; Lin YH; Chu TS; Chang HW; Lin CY; Tsai CT; Lin LY; Chueh SC; Kao TW; Chen YM; Chiang WC; Tsai TJ; Ho YL; Lin SL; Wang WJ; Wu KD;
J Hypertens; 2011 Sep; 29(9):1778-86. PubMed ID: 21738054
[TBL] [Abstract][Full Text] [Related]
13. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.
Karagiannis A; Tziomalos K; Papageorgiou A; Kakafika AI; Pagourelias ED; Anagnostis P; Athyros VG; Mikhailidis DP
Expert Opin Pharmacother; 2008 Mar; 9(4):509-15. PubMed ID: 18312153
[TBL] [Abstract][Full Text] [Related]
14. Long-term effects of adrenalectomy or spironolactone on blood pressure control and regression of left ventricle hypertrophy in patients with primary aldosteronism.
Indra T; Holaj R; Štrauch B; Rosa J; Petrák O; Šomlóová Z; Widimský J
J Renin Angiotensin Aldosterone Syst; 2015 Dec; 16(4):1109-17. PubMed ID: 25271250
[TBL] [Abstract][Full Text] [Related]
15. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.
Epstein M; Williams GH; Weinberger M; Lewin A; Krause S; Mukherjee R; Patni R; Beckerman B
Clin J Am Soc Nephrol; 2006 Sep; 1(5):940-51. PubMed ID: 17699311
[TBL] [Abstract][Full Text] [Related]
16. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study.
Nielsen SE; Persson F; Frandsen E; Sugaya T; Hess G; Zdunek D; Shjoedt KJ; Parving HH; Rossing P
Diabet Med; 2012 Aug; 29(8):e184-90. PubMed ID: 22268920
[TBL] [Abstract][Full Text] [Related]
17. Treatment of primary aldosteronism: Where are we now?
Karagiannis A
Rev Endocr Metab Disord; 2011 Mar; 12(1):15-20. PubMed ID: 21305359
[TBL] [Abstract][Full Text] [Related]
18. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial.
Ando K; Ohtsu H; Uchida S; Kaname S; Arakawa Y; Fujita T;
Lancet Diabetes Endocrinol; 2014 Dec; 2(12):944-53. PubMed ID: 25466242
[TBL] [Abstract][Full Text] [Related]
19. [Metabolic Outcomes of Primary Aldosteronism Patients Receiving Adrenalectomy or Spironolactone Treatments].
Xu C; Chen T; Mo D; Zhang T; Zhou F; Tian H; Ren Y
Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 Nov; 54(6):1227-1232. PubMed ID: 38162054
[TBL] [Abstract][Full Text] [Related]
20. Worsening of lipid metabolism after successful treatment of primary aldosteronism.
Adolf C; Asbach E; Dietz AS; Lang K; Hahner S; Quinkler M; Rump LC; Bidlingmaier M; Treitl M; Ladurner R; Beuschlein F; Reincke M
Endocrine; 2016 Oct; 54(1):198-205. PubMed ID: 27179655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
